Biotech investors are a stubborn and hopeful lot, and many of them will
never give up the ship. While confidence and patience are admirable
traits up to a point, it sometimes feels like some biotech investors
would spin the sun going dark as a positive, as it means no more skin
cancer. In the case of Dendreon (Nasdaq:DNDN),
it's only the true believers and traders who have any confidence that
this company has much of a future. With another very disappointing
quarter in the books, I think the only real debate left to have is
whether the company can survive.
Please click here to continue:
http://www.investopedia.com/stock-analysis/051013/little-left-dendreon-hope-trade-dndn-jnj-mdvn.aspx
No comments:
Post a Comment